The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
HDAC and PI3K Antagonists Cooperate to Inhibit Growth of MYC- Driven Medulloblastoma
Open accessAbstract
SUMMARY Medulloblastoma (MB) is a highly malignant pediatric brain tumor. Despite aggressive therapy, many patients succumb to the disease, and survivors experience severe side effects from treatment. MYC-driven MB has a particularly poor prognosis, and would greatly benefit from more effective therapies. We used an animal model of MYC-driven MB to screen for drugs that decrease viability of tumor cells. Among the most effective compounds were histone deacetylase inhibitors (HDACI). HDACI potently inhibit survival of MYC-driven MB cells in vitro, in part by inducing expression of the FOXO1 tumor suppressor gene. HDACI also synergize with phosphatidylinositol 3-kinase inhibitors (PI3KI) to inhibit tumor growth in vivo. These studies identify an effective combination therapy for the most aggressive form of MB.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drug combination studies and their synergy quantification using the Chou-Talalay method
Chou, T.-C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1947 · Cited by 5,739
Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening
Gupta, P. B., Onder, T. T., Jiang, G., Tao, K., Kuperwasser, C., Weinberg, R. A., & Lander, E. S. (2009) · Cell · doi:10.1016/j.cell.2009.06.034 · Cited by 2,389
Medulloblastoma Comprises Four Distinct Molecular Variants
Northcott, P. A., Korshunov, A., Witt, H., Hielscher, T., Eberhart, C. G., Mack, S., Bouffet, E., Clifford, S. C., Hawkins, C. E., French, P., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.4324 · Cited by 1,339
Self-citationCalnan, D. R., & Brunet, A. (2008) · Oncogene · doi:10.1038/onc.2008.21 · Cited by 1,170
Akt, FoxO and regulation of apoptosis
Zhang, X., Tang, N., Hadden, T. J., & Rishi, A. K. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.03.010 · Cited by 1,103
Olsen, E. A., Kim, Y. H., Kuzel, T. M., Pacheco, T. R., Foss, F. M., Parker, S., Frankel, S. R., Chen, C., Ricker, J. L., Arduino, J. M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.2434 · Cited by 1,055
FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis
Paik, J.-H., Kollipara, R., Chu, G., Ji, H., Xiao, Y., Ding, Z., Miao, L., Tothova, Z., Horner, J. W., Carrasco, D. R., et al. (2007) · Cell · doi:10.1016/j.cell.2006.12.029 · Cited by 1,032
Genome Sequencing of SHH Medulloblastoma Predicts Genotype-Related Response to Smoothened Inhibition
Kool, M., Jones, D. T. W., Jäger, N., Northcott, P. A., Pugh, T. J., Hovestadt, V., Piro, R. M., Esparza, L. A., Markant, S. L., Remke, M., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.004 · Cited by 762
Self-citationCho, Y.-J., Tsherniak, A., Tamayo, P., Santagata, S., Ligon, A., Greulich, H., Berhoukim, R., Amani, V., Goumnerova, L., Eberhart, C. G., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.5148 · Cited by 717
Self-citationBendell, J. C., Rodon, J., Burris, H. A., de Jonge, M., Verweij, J., Birle, D., Demanse, D., De Buck, S. S., Ru, Q. C., Peters, M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.1360 · Cited by 684
Medulloblastomics: the end of the beginning
Northcott, P. A., Jones, D. T. W., Kool, M., Robinson, G. W., Gilbertson, R. J., Cho, Y.-J., Pomeroy, S. L., Korshunov, A., Lichter, P., Taylor, M. D., et al. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3410 · Cited by 663
Self-citationThe role of FoxO in the regulation of metabolism
Gross, D. N., van den Heuvel, A. P. J., & Birnbaum, M. J. (2008) · Oncogene · doi:10.1038/onc.2008.25 · Cited by 540
BET Bromodomain Inhibition of MYC -Amplified Medulloblastoma
Bandopadhayay, P., Bergthold, G., Nguyen, B., Schubert, S., Gholamin, S., Tang, Y., Bolin, S., Schumacher, S. E., Zeid, R., Masoud, S., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2281 · Cited by 352
Self-citationAn Animal Model of MYC-Driven Medulloblastoma
Pei, Y., Moore, C. E., Wang, J., Tewari, A. K., Eroshkin, A., Cho, Y.-J., Witt, H., Korshunov, A., Read, T.-A., Sun, J. L., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2011.12.021 · Cited by 320
Self-citationNakae, J., Barr, V., & Accili, D. (2000) · The EMBO Journal · doi:10.1093/emboj/19.5.989 · Cited by 267
Qian, C., Lai, C.-J., Bao, R., Wang, D.-G., Wang, J., Xu, G.-X., Atoyan, R., Qu, H., Yin, L., Samson, M., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0055 · Cited by 248
Self-citationRational Therapeutic Combinations with Histone Deacetylase Inhibitors for the Treatment of Cancer
Thurn, K. T., Thomas, S., Moore, A., & Munster, P. N. (2011) · Future Oncology · doi:10.2217/fon.11.2 · Cited by 246
Bhadury, J., Nilsson, L. M., Veppil Muralidharan, S., Green, L. C., Li, Z., Gesner, E. M., Hansen, H. C., Keller, U. B., McLure, K. G., & Nilsson, J. A. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1406722111 · Cited by 212
Myc‐induced proliferation and transformation require Akt‐mediated phosphorylation of FoxO proteins
Bouchard, C., Marquardt, J., Brás, A., Medema, R. H., & Eilers, M. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600279 · Cited by 210
Fouladi, M., Park, J. R., Stewart, C. F., Gilbertson, R. J., Schaiquevich, P., Sun, J., Reid, J. M., Ames, M. M., Speights, R., Ingle, A. M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.9119 · Cited by 199
Pipalia, N. H., Cosner, C. C., Huang, A., Chatterjee, A., Bourbon, P., Farley, N., Helquist, P., Wiest, O., & Maxfield, F. R. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014890108 · Cited by 180
HNF4α—role in drug metabolism and potential drug target?
Hwang‐Verslues, W. W., & Sladek, F. M. (2010) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2010.08.010 · Cited by 163
Induction of Mxi1-SR α by FOXO3a Contributes to Repression of Myc-Dependent Gene Expression
Delpuech, O., Griffiths, B., East, P., Essafi, A., Lam, E. W.-F., Burgering, B., Downward, J., & Schulze, A. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01789-06 · Cited by 161
Zhao, X., Liu, Z., Yu, L., Zhang, Y., Baxter, P. A., Voicu, H., Gurusiddappa, S., Luan, J., Su, J. M. F., Leung, H.-C. E., et al. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos061 · Cited by 159
Self-citationPemetrexed and Gemcitabine as Combination Therapy for the Treatment of Group3 Medulloblastoma
Morfouace, M., Shelat, A. A., Jacus, M. O., Freeman, B. B., Turner, D. C., Robinson, S., Zindy, F., Wang, Y., Finkelstein, D., Ayrault, O., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.009 · Cited by 154
Self-citationFoxOs Enforce a Progression Checkpoint to Constrain mTORC1-Activated Renal Tumorigenesis
Gan, B., Lim, C., Chu, G., Hua, S., Ding, Z., Collins, M. P., HU, J. L., Jiang, S., Fletcher-Sananikone, E., Zhuang, L., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.019 · Cited by 151
Milde, T., Lodrini, M., Savelyeva, L., Korshunov, A., Kool, M., Brueckner, L. M., Antunes, A. S. L. M., Oehme, I., Pekrun, A., Pfister, S. M., et al. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-012-0978-1 · Cited by 144
Self-citationBomgaars, L. R., Bernstein, M. L., Krailo, M., KADOTA, R. P., Das, S., Chen, Z., Adamson, P. C., & Blaney, S. M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.6103 · Cited by 140
Wang, L., Brugge, J. S., & Janes, K. A. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1103423108 · Cited by 121
An Integrated In Vitro and In Vivo High-Throughput Screen Identifies Treatment Leads for Ependymoma
Atkinson, J. M., Shelat, A. A., Carcaboso, A. M., Kranenburg, T. A., Arnold, L. A., Boulos, N., Wright, K. D., Johnson, R. A., Poppleton, H., Mohankumar, K. M., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.08.013 · Cited by 118
A statin-regulated microRNA represses human c-Myc expression and function
Takwi, A., Li, Y., Buscaglia, L. E. B., Zhang, J.-W., Choudhury, S., Park, A., Liu, M.-F., Young, K., Park, W., Martin, R. C. G., et al. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201101045 · Cited by 102
Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma
Ecker, J., Oehme, I., Mazitschek, R., Korshunov, A., Kool, M., Hielscher, T., Kiss, J., Selt, F., Konrad, C., Lodrini, M., et al. (2015) · Acta Neuropathologica Communications · doi:10.1186/s40478-015-0201-7 · Cited by 100
Self-citationTriscott, J., Lee, C., Foster, C., Manoranjan, B., Pambid, M. R., Berns, R., Fotovati, A., Venugopal, C., O’Halloran, K., Narendran, A., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4331 · Cited by 95
Self-citationAntagonism between FOXO and MYC Regulates Cellular Powerhouse
Peck, B., Ferber, E. C., & Schulze, A. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00096 · Cited by 89
Survivin as a therapeutic target in Sonic hedgehog-driven medulloblastoma
Brun, S. N., Markant, S. L., Esparza, L. A., Garcia, G., Terry, D., Huang, J.-M., Pavlyukov, M. S., Li, X.-N., Grant, G. A., Crawford, J. R., et al. (2014) · Oncogene · doi:10.1038/onc.2014.304 · Cited by 65
Self-citationShu, Q., Antalffy, B. A., Su, J. M. F., Adesina, A. M., Ou, C., Pietsch, T., Blaney, S. M., Lau, C. C., & Li, X. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2849 · Cited by 65
Self-citationSuberoylanilide hydroxamic acid is effective in preclinical studies of medulloblastoma
Spiller, S. E., Ravanpay, A. C., Hahn, A. W., & Olson, J. M. (2006) · Journal of Neuro-Oncology · doi:10.1007/s11060-006-9142-0 · Cited by 46
Self-citationEfficacy of cabazitaxel in mouse models of pediatric brain tumors
Girard, E. J., Ditzler, S. H., Lee, D., Richards, A., Yagle, K. J., Park, J. C., Khalatbari, H. K., Bobilev, D., Vrignaud, P., & Olson, J. M. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou163 · Cited by 43
Self-citationNorcantharidin impairs medulloblastoma growth by inhibition of Wnt/β-catenin signaling
Cimmino, F., Scoppettuolo, M. N., Carotenuto, M., Antonellis, P. D., Dato, V. D., Vita, G. D., & Zollo, M. (2011) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0645-y · Cited by 40
New developments in medulloblastoma treatment: the potential of a cyclopamine–lovastatin combination
Bar, E. E., & Stearns, D. S. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.2.185 · Cited by 22
Cited by
Intertumoral Heterogeneity within Medulloblastoma Subgroups
Cavalli, F. M. G., Remke, M., Rampasek, L., Peacock, J., Shih, D. J. H., Luu, B., Garzia, L., Torchia, J., Nor, C., Morrissy, A. S., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.05.005 · Cited by 1,219
Self-citationThe MYC oncogene — the grand orchestrator of cancer growth and immune evasion
Dhanasekaran, R., Deutzmann, A., Mahauad-Fernandez, W. D., Hansen, A. S., Gouw, A. M., & Felsher, D. W. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00549-2 · Cited by 986
Risk stratification of childhood medulloblastoma in the molecular era: the current consensus
Ramaswamy, V., Remke, M., Bouffet, E., Bailey, S., Clifford, S. C., Doz, F., Kool, M., Dufour, C., Vassal, G., Milde, T., et al. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1569-6 · Cited by 654
Self-citationNorthcott, P. A., Robinson, G. W., Kratz, C. P., Mabbott, D. J., Pomeroy, S. L., Clifford, S. C., Rutkowski, S., Ellison, D. W., Malkin, D., Taylor, M. D., et al. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0063-6 · Cited by 649
Self-citationStem cell fate in cancer growth, progression and therapy resistance
Lytle, N. K., Barber, A. G., & Reya, T. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0056-x · Cited by 647
Metadata
- Authors
- Pei, Y., Liu, K.-W., Wang, J., Garancher, A., Tao, R., Esparza, L. A., Maier, D. L., Udaka, Y. T., Murad, N., Morrissy, S., Seker-Cin, H., Brabetz, S., Qi, L., Kogiso, M., Schubert, S., Olson, J. M., Cho, Y.-J., Li, X.-N., Crawford, J. R., Levy, M. L., Kool, M., Pfister, S. M., Taylor, M. D., & Wechsler-Reya, R. J.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2016-03
- Volume
- 29
- Issue
- 3
- Pages
- 311-323
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W2300908044
- Cited by
- 276
- References
- 40
- FWCI
- 16.44
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.